Bempedoic acid as treatment for subjects at cardiovascular risk who are statin-intolerant-Reference-Cited by-同舟云学术

Bempedoic acid as treatment for subjects at cardiovascular risk who are statin-intolerant

Published:2023-07-31 Issue:15 Volume:24 Page:1673-1677
ISSN:1465-6566
Container-title:Expert Opinion on Pharmacotherapy
language:en
Short-container-title:Expert Opinion on Pharmacotherapy

Author:

Doggrell Sheila A¹

Affiliation:

1. School of Pharmacy and Medical Sciences, Gold Coast Campus, Griffith University, Gold Coas, Queensland, Australia

Publisher

Informa UK Limited

Subject

Pharmacology (medical),Pharmacology,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/14656566.2023.2242259

Reference16 articles.

1. Bempedoic acid and cardiovascular outcomes in statin-intolerant patients;Nissen SE;N Engl J Med,2023

2. Bempedoic Acid for Primary Prevention of Cardiovascular Events in Statin-Intolerant Patients

3. World Health Organization. Cardiovascular diseases. https://www.who.int/health-topics/cardiovascular-diseases#tab=tab_1 [Last accessed 21 Jun 2023]

4. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American college of cardiology/American heart association task force on clinical practice guidelines;Grundy SM;Circulation,2019

5. Liver-specific ATP-citrate lyase inhibition by bempedoic acid decreased LDL-C and attenuates atherosclerosis;Pinkosky SL;Nat Commun,2016

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. 360-Degree Perspectives on Obesity;Medicina;2023-06-09

2. Circulating levels of proglucagon‐derived peptides are differentially regulated by the glucagon‐like peptide‐1 agonist liraglutide and the centrally acting naltrexone/bupropion and can predict future weight loss and metabolic improvements: A 6‐month long interventional study;Diabetes, Obesity and Metabolism;2023-05-29